Target intelligence / Profile preview

Zinc finger and BTB domain-containing protein 32 (ZBTB32)

Target: ZBTB32
Molecular classification: Transcription factor, Chromatin remodeler, Zinc finger protein, BTB/POZ domain protein

Overview

ZBTB32 is a transcriptional repressor protein encoded by the ZBTB32 gene in humans. It features a BTB/POZ domain (protein-protein interactions), three Krüppel-type C2H2 zinc finger domains (DNA binding), and recruits corepressors (such as N-CoR, HDACs) to induce chromatin repression. ZBTB32 functions mainly in the nucleus to regulate gene expression in activated T and B lymphocytes and is also prominently expressed in testis. It suppresses immune responses, influences cell proliferation, and has documented roles in cancer development and progression. ZBTB32 is considered a hub gene/biomarker in colon cancer and correlates with immune suppression in diffuse large B-cell lymphoma. The protein interacts with FANCC, ZBTB16, VDUP1, Zpo2, and GATA2, mediating context-specific transcriptional repression and chromatin remodeling[1][4].

Other names: Fanconi anemia zinc finger protein (FAZF)Testis zinc finger protein (TZFP)FANCC-interacting protein (FAXF)Zinc finger protein 538 (ZNF538)Repressor of GATA3 (ROG)Myoneurin (mynn)Promyelocytic leukemia zinc finger and Zbtb16-like zinc finger protein (PLZP)FAXPZNF538

Mechanism of action

Not applicable/direct for drugs; as a transcriptional repressor, drugs might act by modulating ZBTB32 expression or activity, but no direct pharmacological modulators are reported

Biological functions

Negative regulation of transcription by RNA polymerase IIRecruitment of corepressors (N-CoR, HDACs)Induction of repressive chromatin statesCell type-specific gene regulation in T cells and B cellsProliferation of natural killer cells and immune cell activation

Disease associations

Cancer (diffuse large B-cell lymphoma, breast cancer, colon cancer)Immune regulation (type 1 diabetes susceptibility, immune cell proliferation)Developmental and epileptic encephalopathy 52Pontocerebellar hypoplasia, type 16

Safety considerations

None specifically reported in the context of direct targeting.As with other transcription factors, potential for broad effects on gene expression if targeted therapeutically

Biomarkers

ZBTB32 expression in colon cancer as a survival biomarkerExpression correlated with aggressive breast cancer phenotype (via GATA3 regulation)

Beyond the preview

Go deeper on Zinc finger and BTB domain-containing protein 32 (ZBTB32).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc finger and BTB domain-containing protein 32 (ZBTB32).

Explore the full profile